Business
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs Canada NewsWire I...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"\n\n\nAI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.\nVANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management at the point of care: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Heartflow, Inc. (NASDAQ: HTFL), CeriBell, Inc. (NASDAQ: CBLL), Medtronic plc (NYSE: MDT), and Abbott Laboratories (NYSE: ABT).\n\n\n\n\n\n\n\nIndustry analysts project AI could reduce healthcare spending by $200 billion to $360 billion annually through current technologies alone, with hospitals capturing $60 billion to $120 billion of those savings from improved clinical operations[3]. The window for adoption is narrow, driven by hospitals pursuing aggressive cost-cutting while 80% simultaneously plan service line expansion, creating demand for technologies that do more with existing infrastructure rather than requiring expensive facility buildouts or staff additions[4].\nVentripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just announced a partnership with Nisg̱a'a Valley Health Authority that establishes a global model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration centers on Ventripoint's VMS+ system, which transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy. This technology enables precise cardiac assessments at the point of care, reducing costs and eliminating the need ...